Patents Assigned to Universitat Zurich
-
Publication number: 20210162019Abstract: The disclosure relates to the treatment, diagnosis and/or prevention of multiple sclerosis (MS) by using an immunodominant protein or peptide. More particular the invention relates to the field of antigen specific immunotherapies, such as the induction of tolerance.Type: ApplicationFiled: June 28, 2019Publication date: June 3, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Mireia SOSPEDRA RAMOS, Roland MARTIN
-
Patent number: 11006866Abstract: The invention relates to a device for measuring the concentration of an analyte in the blood or tissue of a an animal or a human, particularly a premature infant, wherein for measuring said concentration the device comprises a means (30) comprising at least a first and a second permeability with respect to said analyte, wherein the first permeability for said analyte differs from the second permeability for the analyte. Further, the invention relates to a corresponding method.Type: GrantFiled: July 14, 2015Date of Patent: May 18, 2021Assignees: UNIVERSITAT ZURICH, EIDGENOSSISCHE MATERIALPRUFUNGS—UND FORSCHUNGSANSTALTInventors: Lukas Baumann, Katrin Scholler, Markus Rothmaier, Lukas Scherer, Rene Rossi, Damien Paul Joseph Henri De Courten, Martin Wolf
-
Publication number: 20210140948Abstract: The invention relates to a method for multiplex staining of a biological sample involving the use of a buffer combination of blocking buffer, imaging buffer and elution buffer that allows for multiple staining rounds of biological samples. The blocking buffer comprises a compound that is capable of binding to hydrophobic binding sites non-specifically and a sulfhydryl-reactive compound. The imaging buffer is at neutral pH and comprises a radical scavenger, and the elution buffer is at pH lower than 4 and comprises a buffering component, a reducing agent and at least one compound disrupting hydrogen bonds. The invention further relates to buffers used in the practice of the method of the invention, and to a kit containing these buffers.Type: ApplicationFiled: April 24, 2019Publication date: May 13, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Gabriele GUT, Lucas PELKMANS, Markus HERRMANN
-
Publication number: 20210137040Abstract: The present invention provides an improved Helminthosporium turcicum-resistant plant, in particular a maize plant which comprises a polynucleotide with one or more resistance-conferring genes, for example on a truncated chromosome fragment from the accession Pepitilla, as well as a cell, a tissue, a part, grain and seeds thereof, an isolated polynucleotide which comprises one or more resistance-conferring genes against Helminthosporium turcicum, a vector, a transgenic plant cell and a transgenic plant containing this polynucleotide. Furthermore, the invention encompasses suitable markers and their use in introducing resistance or the transgene into a plant, as well as the identification of improved maize plants which comprise a truncated chromosome fragment.Type: ApplicationFiled: December 16, 2020Publication date: May 13, 2021Applicants: KWS SAAT SE & CO. KGAA, UNIVERSITÄT ZÜRICHInventors: Milena OUZUNOVA, Daniela SCHEUERMANN, Beat KELLER, Simon KRATTINGER, Thomas WICKER, Gerhard HERREN, Severine HURNI, Bettina KESSEL, Thomas PRESTERL, Carsten KNAAK
-
Publication number: 20210107932Abstract: The present disclosure relates to derivatives of neamine-based aminoglycoside antibacterial drugs modified in position C6?, C2? and/or C5?. The modifications impart favorable properties regarding activity against ESKAPE pathogens, evasion of resistance traits and increased selectivity, enabling systemic use of the compounds.Type: ApplicationFiled: April 6, 2018Publication date: April 15, 2021Applicants: WAYNE STATE UNIVERSITY, UNIVERSITAT ZURICHInventors: David CRICH, Girish SATI, Amr SONOUSI, Guanyu YANG, Appi Reddy MANDHAPATI, Michael G. PIRRONE, Takayuki KATO, Vikram SARPE, Andrea VASELLA, Erik C. BOTTGER, Sven N. HOBBIE
-
Patent number: 10959829Abstract: The invention relates to a medical implant device for attaching or re-attaching a flexible graft to a bone, comprising: at least a first insert comprising a synthetic osteoconductive and/or osteoinductive material, and a flexible graft, wherein the flexible graft is connected to the at least one insert, particularly prior to surgical implantation of the medical implant device.Type: GrantFiled: January 12, 2016Date of Patent: March 30, 2021Assignee: UNIVERSITAT ZURICHInventors: Jess G. Snedeker, Xiang Li, Elias Bachmann, Sandra Franco Fucentese
-
Patent number: 10953140Abstract: The present invention is directed to a method of producing a tissue graft, comprising at least steps of providing a gel, seeding the gel with cells of at least a first and/or cells of a second type, and culturing of the cells of the first and/or cells of the second type in said gel until the formation of at least one first biostructure in the gel by the cells of the first type and/or the cells of the second type.Type: GrantFiled: July 29, 2014Date of Patent: March 23, 2021Assignee: UNIVERSITAT ZURICHInventors: Ernst Reichmann, Daniela Marino, Agnieszka Sylwia Klar
-
Publication number: 20210070851Abstract: Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.Type: ApplicationFiled: February 22, 2019Publication date: March 11, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Sonia TUGUES, Burkhard BECHER
-
Publication number: 20210071198Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP). matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerise II or RNA polymerase III.Type: ApplicationFiled: April 29, 2020Publication date: March 11, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
-
Publication number: 20210060208Abstract: The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.Type: ApplicationFiled: August 28, 2018Publication date: March 4, 2021Applicant: UNIVERSITÄT ZÜRICHInventors: Simon-Philipp HOERSTRUP, Maximilian Y. EMMERT, Frank BAAIJENS, Anita DRIESSEN-MOL
-
Patent number: 10912497Abstract: A device for detecting and evaluating movements of a user comprises a processing unit, a data memory, a sensor unit with at least one biometric sensor, and a fastening device for fastening the sensor unit on an arm of the user. The processing unit is configured to detect movement data from movement signals generated by the sensor unit and to store the movement data in the data memory. The device further comprises an evaluation module with which secondary movement data, which represent passive arm movements of the user, are filterable out of the movement data. The device enables the detection and evaluation of movements of an arm of the user in an efficient way.Type: GrantFiled: August 23, 2016Date of Patent: February 9, 2021Assignees: TYROMOTION GMBH, ETH ZÜRICH, UNIVERSITÄT ZÜRICH, ZÜRCHER HOCHSCHULE DER KÜNSTEInventors: Karmen Franinovic, Dinis Meier, Samuel Bauer, Roger Gassert, Yeongmi Kim, Kaspar Leuenberger, Andreas Luft, Jeremia Held
-
Publication number: 20210032412Abstract: The invention relates to a polymer structure (1) formed by at least a polymer, wherein said structure (1) comprises a volume (2) and a surface (3), wherein said polymer comprises a plurality of polymer chains connected by linkings, characterized by a linking density, wherein said linking density increases, particularly monotonously, from the surface (3) into the volume (2) of the polymer structure (1).Type: ApplicationFiled: July 17, 2020Publication date: February 4, 2021Applicants: UNIVERSITAT ZURICH, ETH ZURICHInventors: Vincent MILLERET, Benjamin R. SIMONA, Janos VOROS, Martin EHRBAR
-
Patent number: 10897862Abstract: The present invention provides an improved Helminthosporium turcicum-resistant plant, in particular a maize plant which comprises a polynucleotide with one or more resistance-conferring genes, for example on a truncated chromosome fragment from the accession Pepitilla, as well as a cell, a tissue, a part, grain and seeds thereof, an isolated polynucleotide which comprises one or more resistance-conferring genes against Helminthosporium turcicum, a vector, a transgenic plant cell and a transgenic plant containing this polynucleotide. Furthermore, the invention encompasses suitable markers and their use in introducing resistance or the transgene into a plant, as well as the identification of improved maize plants which comprise a truncated chromosome fragment.Type: GrantFiled: September 3, 2014Date of Patent: January 26, 2021Assignees: KWS SAAT SE & CO. KGAA, UNIVERSITÄT ZÜRICHInventors: Milena Ouzunova, Daniela Scheuermann, Beat Keller, Simon Krattinger, Thomas Wicker, Gerhard Herren, Severine Hurni, Bettina Kessel, Thomas Presterl, Carsten Knaak
-
Patent number: 10894828Abstract: The invention relates to a human Interleukin-2 (hIL-2) specific monoclonal antibody (mAb), or antigen binding fragment thereof, the binding of which to hIL-2 inhibits binding of hIL-2 to CD25 and the antibody is characterized by any of the parameters: the variable chain of the mAb comprises the amino acid sequence of SEQ ID NO 005 or SEQ ID NO 006; the binding to hIL-2 is characterized by a dissociation constant (KD)?7.5 nmol/L; the binding to hIL-2 is characterized by an off-rate (Koff)?1×10?4 s?1 and/or the antibody displays no measurable cross-reactivity to murine IL-2.Type: GrantFiled: July 10, 2015Date of Patent: January 19, 2021Assignee: Universität ZürichInventors: Onur Boyman, Natalia Arenas-Ramirez, Chao Zou
-
Patent number: 10889643Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.Type: GrantFiled: January 11, 2017Date of Patent: January 12, 2021Assignee: Universität ZürichInventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
-
Publication number: 20200399401Abstract: The present invention relates to the field of antibodies useful in therapy and diagnosis. It specifically discloses bioconjugates comprising one or more antibodies bound to functionalized, magnetic nanoparticles. These bioconjugates are useful in cancer therapy, particularly for removing circulating tumor cells. The invention further pertains to specific functionalized, magnetic nanoparticles and to the manufacturing of such bioconjugates and such functionalized, magnetic nanoparticles.Type: ApplicationFiled: February 25, 2019Publication date: December 24, 2020Applicants: Universität Zürich, ETH ZurichInventors: Antoine Florent Herzog, Wendelin Jan Stark, Martin Zeltner, Beatrice Beck-Schimmer, Anja Zabel
-
Patent number: 10870846Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.Type: GrantFiled: January 9, 2013Date of Patent: December 22, 2020Assignee: Universität ZürichInventors: Daniel Scott, Andreas Plückthun
-
Patent number: 10835600Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.Type: GrantFiled: September 7, 2016Date of Patent: November 17, 2020Assignee: UNIVERSITÄT ZÜRICHInventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
-
Patent number: 10839898Abstract: A differential memristive circuit includes a normaliser; a first memristor connected between first top and bottom nodes, the first memristive element having a first adjustable resistance value; a first switch connected between the first bottom node and the normaliser; a second memristor connected between a second top node and a second bottom node the second memristor having a second adjustable resistance value; a second switch connected between the second bottom node and the normaliser; and a set of voltage sources that generate voltages greater than 0V. The set of voltage sources generate a first voltage value across the first memristor and a second voltage value across the second memristor. A first output signal depends on the first adjustable resistance value, while a second output signal depends on the second adjustable resistance value. A memristive circuit net output signal is obtained as the difference between the first and second output signals.Type: GrantFiled: July 22, 2018Date of Patent: November 17, 2020Assignee: UNIVERSITÄT ZÜRICHInventors: Giacomo Indiveri, Manu Vijayagopalan Nair
-
Publication number: 20200330623Abstract: Multinuclear complexes and methods for preparing them are provided. The discrete multinuclear complexes include a one or more transition metals and a radioisotope having the same coordination geometry as the transition metal. A bridging ligand is coordinated to the transition metal and the radioisotope to link the transition metal and the radioisotope and pendent ligands are coordinated to each of the transition metal and the radioisotope to stabilise the complex. The multinuclear complexes may include a radioisotope or radioelement that can be detected by medical equipment and may find use in therapy and/or the diagnosis of disease in patients.Type: ApplicationFiled: December 21, 2018Publication date: October 22, 2020Applicants: UNIVERSITY OF THE FREE STATE, UNIVERSITÄT ZÜRICHInventors: Andreas ROODT, Roger Ariel ALBERTO, Angelo FREI, Petrus Pennie MOKOLOKOLO, Robin Kim BOLLINGER, Alice BRINK, Dumisani Vincent KAMA